Antibody fragments: Hope and hype

mAbs

Volumn 2, Issue 1, 2010, Pages 77-83

  Nelson, Aaron L ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody fragments; Antibodydrug conjugate; Fab; scFv; Technology development

Indexed keywords

ABCIXIMAB; ALX 0081; ALX 0681; ANTIBODY; BEVACIZUMAB; BLINATUMOMAB; CANCER ANTIBODY; CERTOLIZUMAB PEGOL; IMMUNOGLOBULIN F(AB) FRAGMENT; MYCOGRAB; NOVOMAB G2; RANIBIZUMAB; SBI 087; TRU 016; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ACUTE CORONARY SYNDROME; ANTIGEN BINDING; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONJUGATION; CROHN DISEASE; DRUG APPROVAL; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SAFETY; DRUG TARGETING; EXTRACTION; FOOD AND DRUG ADMINISTRATION; GENETIC RECOMBINATION; HUMAN; MOLECULAR SIZE; NONHUMAN; PROTEIN DOMAIN; PSORIASIS; RETINA MACULA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; THROMBUS; TREATMENT INDICATION;

ANIMALS; ANTIBODIES, BISPECIFIC; AUTOIMMUNE DISEASES; BIOTECHNOLOGY; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; IMMUNOTOXINS; MICE; NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 77953653252     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.1.10786     Document Type: Review

References (22)

1. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331-7.
2. Pappas DA, Bathon JM, Hanicq D, Yasothan U, Kirkpatrick P. Golimumab. Nat Rev Drug Discov 2009; 8:695-6.
3. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992; 52:3402-8.
4. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50:814-9.
5. Cumber AJ, Ward ES, Winter G, Parnell GD, Wawrzynczak EJ. Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. J Immunol 1992; 149:120-6.
6. Holt LJ, Basran A, Jones K, Chorlton J, Jespers LS, Brewis ND, Tomlinson IM. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng Des Sel 2008; 21:283-8.
7. Jain A, Jain SK. PEGylation: an approach for drug delivery. A review. Crit Rev Ther Drug Carrier Syst 2008; 25:403-47.
8. Sanz L, Cuesta AM, Compte M, Alvarez-Vallina L. Antibody engineering: facing new challenges in cancer therapy. Acta Pharmacol Sin 2005; 26:641-8.
9. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, et al. Single-chain antigenbinding proteins. Science 1988; 242:423-6.
10. Mallender WD, Voss EW Jr. Construction, expression and activity of a bivalent bispecific single-chain antibody. J Biol Chem 1994; 269:199-206.
11. Kurucz I, Titus JA, Jost CR, Segal DM. Correct disulfide pairing and efficient refolding of detergentsolubilized single-chain Fv proteins from bacterial inclusion bodies. Mol Immunol 1995; 32:1443-52.
12. Hayden MS, Linsley PS, Gayle MA, Bajorath J, Brady WA, Norris NA, et al. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol 1994; 1:3-15.
13. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? mAbs 2009; 1:539-47.
14. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100:690-7.
15. Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol 2006; 43:763-71.
16. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56:3055-61.
17. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21:484-90.
18. Milstein C, Cuello AC. Hybrid hybridomas and their use in immunohistochemistry. Nature 1983; 305:537-40.
19. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163:1246-52.
20. Reichert JM, Valge-Archer V. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6:349-56.
21. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-36.
22. Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9:423-30.